Table 1.
Baseline demographic and clinical characteristics of 39 evaluated patients with gemcitabine-refractory advanced pancreatic cancer
| Characteristic | No. of patients | % |
|---|---|---|
| Age | ||
| ≤ 60 years | 25 | 64.1 |
| > 60 years | 14 | 35.9 |
| Sex | ||
| Male | 29 | 74.4 |
| Female | 10 | 25.6 |
| ECOG PS | ||
| 0 | 2 | 5.1 |
| 1 | 35 | 89.7 |
| 2 | 2 | 5.1 |
| Extent of disease | ||
| Locally advanced | 7 | 17.9 |
| Metastatic | 32 | 82.1 |
| Primary tumor location | ||
| Head | 18 | 46.1 |
| Body | 9 | 23.1 |
| Tail | 12 | 30.8 |
| Metastatic site | ||
| Liver | 17 | 43.6 |
| Lung | 7 | 17.9 |
| Distant lymph nodes | 14 | 35.9 |
| Peritoneum | 7 | 17.9 |
| Multiple organs | 13 | 33.3 |
| CA19-9 value (U/mL) | ||
| > 10 times of UNL | 21 | 53.8 |
| ≤ 10 times of UNL | 18 | 46.2 |
| Patients who received 3rd line chemotherapy | 12 | 30.8 |
ECOG PS Eastern Cooperative Oncology Group Performance status, CA19-9 carbohydrate antigen 19-9, UNL upper normal limit